AstraZeneca PLC (AZN) Price History:23.00%(TTM)
Over the latest trailing 12-month period, AstraZeneca PLC (AZN)'s price cagr is +23.00%. The comparable SPY value is +22.70%. Year-to-date price return is -0.22%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$182.28
+$3.32 (+1.86%)
Previous Close: $178.96
Last Session
- Open
- $181.36
- Day High
- $183.67
- Day Low
- $180.39
- Volume
- 1.67M
- Avg Volume
- 1.95M
52-Week Position
60%
of the 52-week price range
- From 52-week high
- -14.31%
- From 52-week low
- +32.84%
52-Week Price Range
52-Week Low
$137.22
Jul 18, 2025
Current Price
$182.28
60% of range
52-Week High
$212.71
Feb 17, 2026
Price Returns by Period
1 Day
+1.86%
7 Days
-1.97%
30 Days
-2.90%
YTD
-0.22%
1 Year
+21.44%
vs 52W High
-14.31%
AZN Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+6.86%
Price CAGR (5Y)
+9.10%
Total Return CAGR (3Y)
+9.05%
Total Return CAGR (5Y)
+11.47%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $182.28 |
| Previous Close | $178.96 |
| Day Range | $180.39 - $183.67 |
| 52-Week Range | $137.22 - $212.71 |
| Volume | 1.67M |
| Average Volume | 1.95M |
| Market Cap | $282.69B |
| % from 52W High | -14.31% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot